ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 2774

Framingham Risk Score Discriminates Coronary Atherosclerosis in Psoriatic Arthritis Patient Better Than Other Cardiovascular Scores Do

Ho Man LAM1, Jiayun Shen2, Qing SHANG3, Tsz Ho CHENG1, Edmund LI1, Ka Tat WONG4 and Lai-Shan TAM5, 1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China, 3Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 4Prince of Wales Hospital, Hong Kong, Hong Kong, 5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: coronary artery disease, psoriatic arthritis and risk assessment

Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with psoriatic arthritis (PsA) are associated with higher cardiovascular (CV) risks. The efficacy of established CV risk scores for predicting CV risks in PsA patients is unknown. The aim of this study is to evaluate the efficacy of different CV risk scores and their European League Against Rheumatism (EULAR) modified versions for discriminating the presence of coronary atherosclerosis evaluated by coronary Computed Tomography Angiography (CTA) in PsA patients.

Methods: Four different CV risk scores namely Framingham risk score (FRS), American College of Cardiology and American Heart Association (ACC/AHA) 10-year atherosclerotic cardiovascular disease (ASCVD), QRISK II and SCORE, together with their EULAR recommended modified versions (1.5 multiplication) were calculated. Presence of overall plaque (P+) and mixed plaque/non-calcified plaque (MP/NCP+), were identified by CTA.

Results: 88 PsA patients [50 ¡Ó 11, male: 54(61.4%)] underwent CTA were recruited. 84, 74, 88 and 88 patients were eligible to calculate FRS, ASCVD, QRISKII and SCORE respectively. All CV risk scores were significantly higher in both P+ and MP/NCP+ patients [FRS: P+ (13.5 ¡Ó 8.7 vs 6.5 ¡Ó 5.3; p<0.001), MP/NCP+ (13.7 ¡Ó 9.0 vs 7.4 ¡Ó 5.7; p<0.001); ASCVD: P+ (7.0 ¡Ó 5.3 vs 3.4 ¡Ó 3.4; p<0.001), MP/NCP+ (7.1 ¡Ó 5.5 vs 3.9 ¡Ó 3.6; p=0.005); QRISKII: P+ (9.6 ¡Ó 7.8 vs 6.4 ¡Ó 6.6; p=0.047), MP/NCP+ (9.9 ¡Ó 8.2 vs 6.5 ¡Ó 6.3; p=0.035); SCORE: P+ (1.4 ¡Ó 1.4 vs 0.5 ¡Ó 0.8; p=0.001), MP/NCP+ (1.4 ¡Ó 1.4 vs 0.6 ¡Ó 1.0; p=0.004)]. Areas under the receiver operating characteristic (ROC) curves, differentiating P+ and MP/NCP+, were 0.77 (0.67 ¡V 0.88 p<0.001) and 0.73 (0.62 ¡V 0.84 p<0.001) for FRS, 0.76 (0.636 ¡V 0.87 p<0.001) and 0.72 (0.60 ¡V 0.84 p=0.001) for ASCVD, 0.65 (0.53 ¡V 0.78, p=0.018) and 0.64 (0.52 ¡V 0.76 p=0.026) for QRISKII, 0.72 (0.614 ¡V 0.831 p<0.001) and 0.68 (0.56 ¡V 0.79 p=0.005) for SCORE, respectively. 38(45.2%), 23(31.1%), 6(6.8%) and 1(1.1%) patients were classified as having high CV risks according to FRS>10%, ASCVD>7.5%, QRISK II>20% and SCORE>5% respectively. By applying the EULAR multiplication factor, 51(60.7%), 32(43.2%), 22(25%) and 4(4.5%) patients were reclassified as having high CV risks. The sensitivity of FRS>10% increased from 56.9% to 76.5% for P+ (Figure 1), and from 53.3% to 75.6% for MP/NCP+ (Figure 2). Other risk scores generally underestimated coronary atherosclerosis (Figure 1&2).

Conclusion: FRS was better correlated with coronary atherosclerosis than other CV risk scores. EULAR modification further improved the sensitivity of FRS.

 


Disclosure: H. M. LAM, None; J. Shen, None; Q. SHANG, None; T. H. CHENG, None; E. LI, None; K. T. WONG, None; L. S. TAM, None.

To cite this abstract in AMA style:

LAM HM, Shen J, SHANG Q, CHENG TH, LI E, WONG KT, TAM LS. Framingham Risk Score Discriminates Coronary Atherosclerosis in Psoriatic Arthritis Patient Better Than Other Cardiovascular Scores Do [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/framingham-risk-score-discriminates-coronary-atherosclerosis-in-psoriatic-arthritis-patient-better-than-other-cardiovascular-scores-do/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/framingham-risk-score-discriminates-coronary-atherosclerosis-in-psoriatic-arthritis-patient-better-than-other-cardiovascular-scores-do/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology